Navigation Links
SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
Date:1/13/2011

BOTHELL, Wash., Jan. 13, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that its common stock is expecting to begin trading in the over-the counter (OTC) market beginning January 13, 2011 under the trading symbol 'SCLR'.  The common stock is expected to be quoted on the OTC Bulletin Board and OTCQB™ Market on that date.  SCOLR's common stock will cease trading on the NYSE Amex Exchange at the close of business on January 12, 2011.

The OTCQB™ Market is a market tier for OTC-traded companies that are registered and reporting with the Securities and Exchange Commission. Quote information can be obtained by visiting www.otcmarkets.com.  

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter, and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:Any statements made in this press release that relate to plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements, including statements regarding the anticipated date of quotation of SCOLR Pharma, Inc. common stock are subject to risks and uncertainties.  Factors that could cause these forward-looking statements to differ from actual results include delays in quotation, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.Contacts:Investor Relations: SCOLR Pharma, Inc. 425.368.1050
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
2. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
3. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
4. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
5. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
6. SCOLR Pharma, Inc. Licenses Dietary Supplements
7. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
8. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
11. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... SPRING, Md. , March 29, 2017 On March ... (ocrelizumab) to treat adult patients with relapsing forms of ... This is the first drug approved by the FDA ... a health care professional.  "Multiple sclerosis ... said Billy Dunn , M.D., director of the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits from the expanding ... Frontier Data, the legal cannabis market is projected to create 283,422 ... the United States , as well as the economic ... that drives growth in this sector. Medical cannabis is now legal ...
(Date:3/28/2017)... 28, 2017 "Chemotherapy Induced Neutropenia (CIN) – Market Insights, ... and global market trends of the Chemotherapy Induced Neutropenia for the ... Europe ( France , ... , UK) and Japan , as well ... of the world (RoW). The Report covers the therapeutics ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage ... Intercontinental Time Square, New York. , The program will be led by ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield ... Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, and ... estate valuation industry for more than 40 years. , “Ruel is a great ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, ... a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey and ... emphasizes the fact that medication IS NOT the only solution to deal with thyroid ...
Breaking Medicine News(10 mins):